TheraJects transdermal technology addresses these areas by enabling:
- Pain-free, minimally invasive interstitial fluid access in the skin -- avoiding GI
- Tailored release profile -- rapid onset and/or continuous delivery
- Reduced drug dose and/or extended activity due to enhanced bioavailability
- Improved storage and transportation stability
VaxMAT and DrugMATcan help solve several important problems in the delivery of drugs and
vaccines by dramatically overcoming the limits of conventional transdermal and hypodermic
drug delivery. Conventional patch systems cannot deliver molecules larger than 500 Daltons
(atomic mass units), and therefore cannot deliver large molecules, proteins, and vaccines.
DrugMAT and VaxMAT have no molecular weight limits and, therefore, can transdermally
delivery large molecules such as proteins, vaccines, and genetic materials. DrugMAT and
VaxMAT will be developed for broad use because of their advantages in flexible release profile,
dose, safety, efficiency, patient comfort, ease of use, and cost of production. With TheraJectMAT
and VaxMAT, TheraJect has achieved patent protected technological breakthroughs that should
enable safe, effective, and economical transdermal delivery of large molecules and small
molecules such as pain-related drugs unsuitable for currently available transdermal systems.